Gupta Anurag, Wang Shouyan, Marko Aimee, Joshi Penny, Ethirajan Manivannan, Chen Yihui, Yao Rutao, Sajjad Munawwar, Kopelman Raoul, Pandey Ravindra K
1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
2. Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA;
Theranostics. 2014 Mar 16;4(6):614-28. doi: 10.7150/thno.8478. eCollection 2014.
In this report we demonstrate the outstanding advantages of multifunctional nanoplatforms for cancer-imaging and therapy. The non-toxic polyacrylamide (PAA) nanoparticles (size:18-25 nm) formulation drastically changed the pharmacokinetic profile of the ¹²⁴I- labeled chlorophyll-a derivative (formulated in 10% ethanol in PBS) with a remarkable enhancement in tumor uptake, and significantly reduced uptake in spleen and liver. Among the various nanoformulations investigated, the ¹²⁴I- labeled photosensitizer (dose: 0.6142 MBq), and the cyanine dye-nanoparticles (CD-NP) conjugate (dose 0.3 μmol/kg) in combination showed great potential for tumor imaging (PET/NIR fluorescence) in BALB/c mice bearing Colon26 tumors. Compared to free non-labeled photosensitizer, the corresponding PAA nanoformulation under similar treatment parameters showed a remarkable enhancement in long-term tumor cure by PDT (photodynamic therapy) and provides an opportunity to develop a single nanoplatform for tumor-imaging (PET/fluorescence) and phototherapy, a practical "See and Treat" approach.
在本报告中,我们展示了多功能纳米平台在癌症成像和治疗方面的突出优势。无毒的聚丙烯酰胺(PAA)纳米颗粒(尺寸:18 - 25纳米)制剂极大地改变了¹²⁴I标记的叶绿素-a衍生物(在PBS中10%乙醇中配制)的药代动力学特征,显著提高了肿瘤摄取,并显著降低了在脾脏和肝脏中的摄取。在所研究的各种纳米制剂中,¹²⁴I标记的光敏剂(剂量:0.6142 MBq)与花菁染料纳米颗粒(CD-NP)缀合物(剂量0.3 μmol/kg)联合使用,在携带Colon26肿瘤的BALB/c小鼠中显示出在肿瘤成像(PET/近红外荧光)方面的巨大潜力。与游离的未标记光敏剂相比,在相似治疗参数下相应的PAA纳米制剂通过光动力疗法(PDT)在长期肿瘤治愈方面显示出显著增强,并为开发用于肿瘤成像(PET/荧光)和光疗的单一纳米平台提供了机会,这是一种实用的“可视即治疗”方法。